HOWL earnings analysis
What we found in HOWL's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Werewolf Therapeutics reported disappointing financial results for Q4 2026, with zero revenue and an improved diluted EPS of -$0.20, surpassing analyst expectations. The company continues to struggle with significant losses, prompting management to evaluate strategic alternatives to enhance shareholder value amidst ongoing operational concerns.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Improved EPS Compared to Consensus
- Diluted EPS of -$0.20, beating the estimated EPS of -$0.34 by $0.14.
- Zero Revenue Again
- The company reported $0.0 revenue, marking a continuation of revenue decline compared to estimates of $600K.
- Cash Reserves Update
- As of March 31, 2026, cash and cash equivalents total $46.5 million.
- Debt Repayment Completed
- All amounts owed under the K2HV Loan Agreement were repaid totaling approximately $31.4 million.
- Strategic Alternatives Under Evaluation
- Management indicated ongoing evaluation of strategic options to improve shareholder value.
- Pending Regulatory Changes
- Ongoing healthcare reform proposals could further complicate the pharmaceutical pricing landscape affecting future operations.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- No Revenue Realized
- The firm reported zero revenue again, raising concerns about its ability to sustain operations.
- Significant Net Losses
- Net loss for the quarter was $13.5 million, continuing a trend of substantial operating losses.
- Going Concern Doubts
- Management expressed substantial doubt about the ability to continue operations for the next twelve months.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.2
What they said about what is next.
Outlook deferred to earnings press release / call.
The filing reads worse than the one before it.
What came before.
- 10-K · March 27, 2026
- Werewolf Therapeutics (HOWL) is conducting a strategic review and implemented a restructuring (64% workforce reduction) to extend capital while pursuing a sale, license or other alternatives; the company reported…
- 10-Q · November 7, 2024
- Werewolf reported zero collaboration revenue for Q3 (three months ended September 30, 2024) versus $5,897 thousand in the prior-year quarter, while operating loss widened to $17,124 thousand (from $9,251 thousand) and…
- 10-Q · August 8, 2024
- Werewolf reported collaboration revenue of $1,143 (in thousands) for Q2 and a GAAP diluted loss per share of $(0.43). Revenue recognized in the quarter reflected the final recognition of the Jazz collaboration (deferred…
- 10-Q · November 14, 2023
- Werewolf reported Q3 revenue of $5,897,000 (collaboration revenue), up from $4,970,000 in Q3 2022, and reduced its net loss to $(8,285,000) versus $(11,943,000) a year ago. GAAP diluted EPS improved to $(0.23) from…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing HOWL makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever